-
公开(公告)号：US06465247B1
公开(公告)日：2002-10-15
申请号：US09607529
申请日：2000-06-29
IPC分类号： C12N506
CPC分类号： C12Q1/6881 , C12N5/0647 , C12N2501/125 , C12N2501/14 , C12N2501/145 , C12N2501/22 , C12N2501/23 , C12N2501/26 , C12N2503/00 , C12Q2600/158
摘要： A substantially enriched mammalian hematopoietic cell subpopulation is provided, which is characterized by progenitor cell activity for myeloid lineages, but lacking the potential to differentiate into lymphoid lineages. This population is further divided into specific myeloid progenitor subsets, including a common myeloid progenitor cells (CMP), megakaryocyte/erythroid progenitor cells (MEP) and granulocyte/monocyte lineage progenitor (GMP). Methods are provided for the isolation and culture of these subpopulations. The CMP population gives rise to all myeloid lineages, and can give rise to the two additional and isolatable progenitor populations that are exclusively committed to either the erythroid/megakaryocytic or myelomonocytic lineages. The cell enrichment methods employ reagents that specifically recognize CDw127 (IL-7 receptor &agr;); CD117 (c-kit) protein, in conjunction with other markers expressed on lineage committed cells. These cells give rise to a variety of myeloid cells, including megakaryocytes, granulocytes, dendritic cells and erythroid cells, as evidenced by their growth and differentiation in vitro and in vivo.
摘要翻译： 提供了基本上富集的哺乳动物造血细胞亚群，其特征在于骨髓谱系的祖细胞活性，但缺乏分化成淋巴谱系的潜力。 该群体进一步分为特定的骨髓祖细胞亚群，包括常见的髓系祖细胞（CMP），巨核细胞/红细胞祖细胞（MEP）和粒细胞/单核细胞谱系祖细胞（GMP）。 提供了用于分离和培养这些亚群体的方法。 CMP群体产生所有骨髓谱系，并且可以产生专门致力于红细胞/巨核细胞或骨髓单核细胞谱系的两个另外的和可分离的祖细胞群体。 细胞富集方法使用特异性识别CDw127（IL-7受体α）的试剂; CD117（c-kit）蛋白，与在谱系确定细胞上表达的其他标志物结合。 这些细胞产生各种骨髓细胞，包括巨核细胞，粒细胞，树突状细胞和红细胞，其体外和体内的生长和分化证明。
-
42.发明授权Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof 失效基于T细胞受体可变区内的独特序列的诊断试剂及其用途
公开(公告)号：US4886743A
公开(公告)日：1989-12-12
申请号：US726502
申请日：1985-04-24
IPC分类号： A61K38/00 , C07H21/04 , C07K14/00 , C07K14/705 , C07K14/725 , C07K16/00 , C07K16/28 , C07K19/00 , C12N15/00 , C12N15/09 , C12P21/08 , C12Q1/68 , G01N33/50 , G01N33/53 , G01N33/564 , G01N33/569 , G01N33/574 , G01N33/576 , G01N33/577
CPC分类号： C07K16/2809 , C12Q1/6876 , C12Q1/6883 , G01N33/5091 , G01N33/564 , G01N33/56972 , G01N33/56988 , G01N33/57415 , G01N33/576 , A61K38/00 , G01N2800/102 , G01N2800/245 , Y10S435/974 , Y10S436/813 , Y10T436/117497
摘要： This invention provides a reagent capable of binding to T cells and having specificity for a unique sequence within the variable region of the .beta. chain of the T cell receptor, the presence of increased number of T cells carrying the unique sequence relative to the number of T cells carrying the sequence present in a normal subject being associated with a specific disease. Specific diseases such as human cancers, e.g. lymphomas; autoimmune diseases, e.g. rheumatoid arthritis; Alzheimer's disease; infectious diseases, e.g. those caused by bacteria, yeast or parasite; or allergies, may be diagnosed as follows. A suitable sample containing T cells is obtained from a subject. The sample is contacted under appropriate conditions with such a reagent. If the subject's cells contain the unique sequence, a detectable complex is formed between the reagent and T cells which contain the sequence. By quantitatively determining the number of T cells containing the sequence present in the complex formed and comparing this number with the number of T cells carrying the sequence determined for a normal subject, the disease with which the unique sequence is associated may be diagnosed. Similar reagents and methods may also be used to detect organ transplant rejection.
摘要翻译： 本发明提供了能够结合T细胞并且对T细胞受体的β链的可变区内的唯一序列具有特异性的试剂，相对于T细胞数目的携带具有唯一序列的T细胞数量的增加 携带存在于正常受试者中的序列的细胞与特定疾病相关。 特定疾病，如人类癌症，例如 淋巴瘤 自身免疫性疾病，例如 类风湿关节炎; 阿尔茨海默氏病; 传染病，例如 那些由细菌，酵母或寄生虫引起的; 或过敏，可以诊断如下。 从受试者获得含有T细胞的合适样品。 样品在适当的条件下与这种试剂接触。 如果受试者的细胞含有唯一的序列，则在包含该序列的试剂和T细胞之间形成可检测的复合物。 通过定量测定含有存在于所形成的复合物中的序列的T细胞的数目，并将该数目与携带为正常受试者确定的序列的T细胞的数目进行比较，可以诊断与该独特序列相关的疾病。 类似的试剂和方法也可用于检测器官移植排斥反应。
-
公开(公告)号：US20190048077A1
公开(公告)日：2019-02-14
申请号：US16079927
申请日：2017-05-01
IPC分类号： C07K16/28 , A61K31/343 , A61K31/198 , A61K31/473 , A61K31/7004 , A61K38/05 , A61K38/16 , A61K38/17 , A61K49/00 , A61P41/00
摘要： Aspects of the present disclosure include methods of treating a subject to reduce adhesion formation, the method comprising administering to a subject in need of thereof an agent that that targets adhesion-formation by injured mesothelial cells. The agent can act at a variety of checkpoints in the development of adhesions by injured mesothelial cells, including: targeting the injured mesothelial cells for destruction, recruiting inflammatory macrophages to the site of adhesion, preventing neutrophil recruitment to the site of adhesion, and/or inhibiting the expression or activity of a gene product whose expression is induced in the injured mesothelial cells. Compositions and kits for performing the methods are also provided.
-
公开(公告)号：US08758750B2
公开(公告)日：2014-06-24
申请号：US13394060
申请日：2010-09-15
IPC分类号： A61K39/395 , A61K39/00
CPC分类号： C07K16/2803 , A61K39/39558 , A61K51/1093 , A61K2039/507 , C07K16/2887 , C07K2317/732 , C07K2317/734 , C07K2317/77
摘要： Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2.
摘要翻译： 提供了用于治疗血液癌，特别是淋巴瘤和白血病的方法，包括但不限于骨髓性和淋巴细胞性白血病。 CD47特异性抗体的组合; 并向癌症相关细胞表面标志物特异性给予患者，并提供癌细胞负担的协同降低。 抗体的组合可以包含多个单特异性抗体，或双特异性或多特异性抗体。 感兴趣的标记包括但不限于CD20，CD22，CD52，CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; 和HAVCR2。
-
公开(公告)号：US20130209415A1
公开(公告)日：2013-08-15
申请号：US13701425
申请日：2011-06-01
IPC分类号： C12N5/071
CPC分类号： C12N5/0657 , A61K35/12 , A61K35/34 , C12N2501/115 , C12N2501/155 , C12N2501/16 , C12N2501/165 , C12N2501/727 , C12N2506/02
摘要： Composition and methods are provided for the prospective enrichment of human cardiovascular progenitor cells, which can be differentiated into cardiomyocytes, from in vitro cultures of stem cells. The stem cells are cultured in conditions permissive for differentiation into cardiovascular progenitor cells, and cardiovascular progenitor cells are sorted for expression of one or more of the markers ROR2, CD13, KDR and PDGFαR, where the progenitor cells positively express these markers. Highly enriched populations of cardiomyocyte lineage cells can be obtained.
摘要翻译： 提供组合物和方法用于从干细胞的体外培养物中将人心脏祖细胞的前瞻性富集（其可以分化为心肌细胞）。 干细胞在允许分化为心血管祖细胞的条件下培养，并且分选心血管祖细胞以表达一种或多种标志物ROR2，CD13，KDR和PDGFαR，其中祖细胞阳性表达这些标记物。 可以获得高浓度的心肌细胞谱系细胞。
-
公开(公告)号：US20120282174A1
公开(公告)日：2012-11-08
申请号：US13394060
申请日：2010-09-15
IPC分类号： A61K39/395 , A61K51/10 , C07K16/30 , A61P35/00 , A61P35/02
CPC分类号： C07K16/2803 , A61K39/39558 , A61K51/1093 , A61K2039/507 , C07K16/2887 , C07K2317/732 , C07K2317/734 , C07K2317/77
摘要： Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2.
摘要翻译： 提供了用于治疗血液癌，特别是淋巴瘤和白血病的方法，包括但不限于骨髓性和淋巴细胞性白血病。 CD47特异性抗体的组合; 并向癌症相关细胞表面标志物特异性给予患者，并提供癌细胞负担的协同降低。 抗体的组合可以包含多个单特异性抗体，或双特异性或多特异性抗体。 感兴趣的标记包括但不限于CD20，CD22，CD52，CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; 和HAVCR2。
-
公开(公告)号：US08232071B2
公开(公告)日：2012-07-31
申请号：US12817105
申请日：2010-06-16
申请人： Irving L. Weissman , Naoki Hosen
发明人： Irving L. Weissman , Naoki Hosen
CPC分类号： G01N33/57426 , C12Q1/34 , G01N33/5011
摘要： Acute myeloid leukemia stem cells (AMLSC) are identified. The cells can be prospectively isolated or identified from patient samples, and are shown to possess the unique properties of cancer stem cells in functional assays for cancer stem cell self-renewal and differentiation, and in cancer diagnosis.
摘要翻译： 确定急性骨髓性白血病干细胞（AMLSC）。 可以从患者样品前瞻性分离或鉴定细胞，并且在癌症干细胞自我更新和分化以及癌症诊断的功能测定中显示具有癌干细胞的独特性质。
-
公开(公告)号：US08153388B2
公开(公告)日：2012-04-10
申请号：US12875025
申请日：2010-09-02
CPC分类号： G01N33/57426 , C12N5/0695 , G01N33/5011 , G01N2333/70589 , G01N2333/70596 , G01N2333/715
摘要： Isolated populations of leukemic stem cells are provided. The cells are useful for experimental evaluation, and as a source of lineage and cell specific products, and as targets for the discovery of factors or molecules that can affect them. Detection of leukemic stem cells is useful in predicting disease progression, relapse, and development of drug resistance. Proliferation of LSC may be inhibited through interfering with activation of the β-catenin pathway. Methods are provided for the clinical staging of pre-leukemia and leukemias by differential analysis of hematologic samples for the distribution of one or more hematopoietic stem or progenitor cell subsets.
摘要翻译： 提供了白血病干细胞的分离群体。 这些细胞可用于实验评价，也可用作谱系和细胞特异性产物的来源，也可用于发现影响它们的因子或分子。 白血病干细胞的检测可用于预测疾病进展，复发和耐药发展。 LSC的增殖可能通过干扰β-联蛋白途径的活化来抑制。 通过差异分析血液样品以分配一个或多个造血干细胞或祖细胞亚群，为白血病和白血病的临床分期提供方法。
-
公开(公告)号：US20090191202A1
公开(公告)日：2009-07-30
申请号：US12321215
申请日：2009-01-15
IPC分类号： A61K39/395 , C12N5/08
CPC分类号： A61K38/1709 , A61K35/14 , C07K16/2896 , G01N33/5091 , G01N33/5094 , G01N33/566 , G01N33/574 , G01N2800/22
摘要： Methods are provided to manipulate phagocytosis of cells, including hematopoietic cells, e.g. circulating hematopoietic cells, bone marrow cells, etc.; and solid tumor cells. In some embodiments of the invention the circulating cells are hematopoietic stem cells, or hematopoietic progenitor cells, particularly in a transplantation context, where protection from phagocytosis is desirable. In other embodiments the circulating cells are leukemia cells, particularly acute myeloid leukemia (AML), where increased phagocytosis is desirable.
摘要翻译： 提供了用于操纵细胞吞噬作用的方法，包括造血细胞，例如， 循环造血细胞，骨髓细胞等; 和实体瘤细胞。 在本发明的一些实施方案中，循环细胞是造血干细胞或造血祖细胞，特别是在移植上下文中，其中希望保护免受吞噬作用。 在其他实施方案中，循环细胞是白血病细胞，特别是急性骨髓性白血病（AML），其中希望增加吞噬作用。
-
50.发明申请公开(公告)号：US20090191164A1
公开(公告)日：2009-07-30
申请号：US12353098
申请日：2009-01-13
CPC分类号： C12N5/0647 , A61K35/28 , A61K35/51 , G01N15/042 , G01N33/5073 , G01N2015/149 , G01N2500/00
摘要： A substantially enriched human multipotent progenitor cell population is provided, which is characterized as a progenitor cell capable of giving rise to the multipotent lineage but which lacks certain long-term self-renewal properties of the hematopoietic stem cell. Methods are provided for the isolation and culture of these cells. The cell enrichment methods employ reagents that specifically recognize CD34, CD38, CD90 and CD45RA, in conjunction with lineage specific markers. These cells give rise to all types of hematopoietic cells, e.g. myeloid and lymphoid cells, in vivo.
摘要翻译： 提供了一种基本上富集的人多能祖细胞群，其特征在于能够产生多能谱系但缺乏造血干细胞某些长期自我更新性质的祖细胞。 提供了用于分离和培养这些细胞的方法。 细胞富集方法使用特异性识别CD34，CD38，CD90和CD45RA的试剂，与谱系特异性标记物结合。 这些细胞产生所有类型的造血细胞，例如， 骨髓和淋巴细胞，体内。
-
-
-
-
-
-
-
-
-
搜索结果
55 条记录 (耗时 0.034 秒)
